X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Lead Product(s): Denifanstat,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ascletis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
An analysis of the full patient population at 52 weeks will evaluate the impact of TVB-2640 (denifanstat) treatment or placebo as assessed by biopsy, with primary efficacy endpoints that include improvement in NASH activity score or improvement in fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Denifanstat (TVB-2640), the company’s lead product candidate, is an oral, selective, first-in-class fatty acid synthase inhibitor. Denifanstat’s unique mechanism of action directly targets the primary drivers of NASH by reducing excess liver fat.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Denifanstat (formerly known as TVB-2640) is a wholly owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
TVB-2640 (denifanstat) is a wholly owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Sagimet will present results from an ongoing Phase 2 clinical trial of TVB-2640 in NASH patients in the poster entitled "Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 Study of FASN Inhibitor TVB-2640.
Lead Product(s): Tvb-2640
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
